Bionomics has a lengthy history of successful alliances with industry and academia. In general, the company seeks to develop compounds to successful proof of concept in human clinical trials. We are open to expressions of interest with respect to partnership at all stages of development.
Additionally, Bionomics is open to in-licensing proposals that are in alignment with the company’s overall therapeutic focus in CNS diseases.
For any partnering enquiries, please contact us here
Small molecule Kv3.1 / Kv3.2 potassium ion channels activators for improving cognitive dysfunction and negative symptoms in schizophrenia and other illnesses such as Autism Spectrum Disorder and Alzheimer’s Disease
Small molecule pan Nav (1.7/1.8/1.9) inhibitors for the treatment of chronic pain
A multi-modal small molecule tubulin polymerization inhibitor has completed four Phase 1 and Phase 2 clinical trials
A humanized monoclonal antibody to LGR5, a cancer stem cell receptor has completed Phase 1 clinical trials
Merck α7 receptor PAM Collaboration
- In June 2014 Bionomics entered into in 2014 to develop α7 receptor PAMs targeting cognitive dysfunction associated with Alzheimer’s disease and other central nervous system conditions
- Merck funds all R&D activities including clinical development and WW commercialization of any products from collaboration
- Milestone payments of US$20M upfront and US$10M in 2017 when 1st compound entered Phase 1 clinical trials
- Eligible to receive up to US$465M in additional milestone payments for certain development and commercial milestones
In February 2021 Bionomics entered into a Memorandum of Understanding with EmpathBio, which sets out an initial collaborative framework of preclinical studies to collectively explore a combination drug treatment regimen with BNC210 and EMP-01 (3,4-Methylenedioxymethamphetamine
MDMA-assisted psychotherapy has demonstrated significant symptom improvement in PTSD patients and FDA has granted a Breakthrough Therapy designation to MDMA-assisted psychotherapy. Empath Bio is developing MDMA derivatives that may permit the entactogenic effects of MDMA to be separated from some of the known adverse effects.
Exclusive BNC101 Oncology License Agreement for the Development of CAR-T Therapeutics
On 19 November 2020 Bionomics announced that it has entered into an exclusive Agreement to license Bionomics’ BNC101 oncology drug candidate to Carina Biotech (Carina), for the development of Chimeric Antigen Receptor T cell (CAR-T) therapy, which harnesses the body’s immune system to fight cancer.
Under the worldwide, exclusive License Agreement, Carina will fund all research and development activities. Bionomics is eligible to receive up to A$118 million in clinical & development milestones plus royalty payments if Carina fully develops and markets the new therapy. In the event that Carina sub-licenses the CAR-T treatment, Bionomics is eligible to share in the sub-licensing revenues in early clinical development and receive a substantial double-digit portion of the revenues in later stages of clinical development.
In September 2021, Carina announced that it plans to initiate a clinical trial of BNC101 CAR-T therapy for the treatment of advanced colorectal (bowel) cancer in late 2022.